Piper Sandler Reiterates Overweight on Solid Biosciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin has reiterated an Overweight rating on Solid Biosciences (NASDAQ:SLDB) and maintained a $20 price target.
June 21, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Biren Amin has reiterated an Overweight rating on Solid Biosciences (NASDAQ:SLDB) and maintained a $20 price target.
The reiteration of an Overweight rating and a maintained price target of $20 by a reputable analyst can boost investor confidence in Solid Biosciences, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100